Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Japan flag Japan · Delayed Price · Currency is JPY
4,060.00
-15.00 (-0.37%)
Apr 28, 2026, 3:30 PM JST
1.15%
Market Cap 153.75B
Revenue (ttm) 75.66B
Net Income (ttm) -3.83B
Shares Out 37.87M
EPS (ttm) -100.31
PE Ratio n/a
Forward PE 82.08
Dividend 190.00 (4.68%)
Ex-Dividend Date Mar 30, 2026
Volume 128,900
Average Volume 100,685
Open 4,075.00
Previous Close 4,075.00
Day's Range 4,015.00 - 4,090.00
52-Week Range 3,540.00 - 4,445.00
Beta 0.15
RSI 42.00
Earnings Date May 13, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger... [Read more]

Sector Healthcare
Founded 1917
Employees 1,126
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4521
Full Company Profile

Financial Performance

In fiscal year 2025, Kaken Pharmaceutical's revenue was 94.04 billion, an increase of 30.52% compared to the previous year's 72.04 billion. Earnings were 13.95 billion, an increase of 73.77%.

Financial Statements

News

There is no news available yet.